Health Technology

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

Retrieved on: 
Friday, July 19, 2024

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024.
  • Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The Company’s fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units.
  • Revenues were $3,151,851, representing a decrease of $141,082, or 4%, from $3,292,933 for the three months ended May 31, 2023.
  • Net loss attributed to Novo Integrated Sciences, Inc. for the three months ended May 31, 2024, was $13,741,903, representing an increase of $12,244,573, or 818%, from $1,497,330 for the three months ended May 31, 2023.

Gene Therapy Agreements Analysis Report and Directory 2016-2024: Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com

Retrieved on: 
Friday, July 19, 2024

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma companies.

Key Points: 
  • Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma companies.
  • Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2024.
  • The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals.
  • This report contains a comprehensive listing of 740 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties.

Mirion Announces Earnings Release and Conference Call Date for Second Quarter 2024

Retrieved on: 
Friday, July 19, 2024

Mirion (NYSE: MIR) announced today that it will release financial results for second quarter 2024 after market close on Thursday, August 1, 2024.

Key Points: 
  • Mirion (NYSE: MIR) announced today that it will release financial results for second quarter 2024 after market close on Thursday, August 1, 2024.
  • Following the news release, the company will host a conference call the next day, Friday, August 2, 2024, at 11:00 am ET to discuss the results.
  • Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call.
  • An archived replay of the call will also be available on the Investors portion of the Mirion website at https://ir.mirion.com/ .

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

Retrieved on: 
Thursday, July 18, 2024

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (“SBLC”).

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (“SBLC”).
  • The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company.
  • With this initial disbursement the Company expects final distribution to follow on or before August 2.
  • As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetization program.

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Retrieved on: 
Thursday, July 18, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024.
  • The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024.
  • Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio .
  • A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Retrieved on: 
Thursday, July 18, 2024

Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately.

Key Points: 
  • Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately.
  • Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
  • Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health.
  • “With Guardant Health's innovative approaches to cancer detection and care, I am eager to contribute to their mission of improving patient outcomes through advanced diagnostics,” said Dr. Hidalgo.

Hanger Ventures Announces Inaugural Investment

Retrieved on: 
Thursday, July 18, 2024

Hanger Ventures, a Hanger, Inc. business whose primary objective is to advance orthotics and prosthetics innovation and improve patient outcomes, today announced its debut investment in Bionic Power, a Canadian-based firm.

Key Points: 
  • Hanger Ventures, a Hanger, Inc. business whose primary objective is to advance orthotics and prosthetics innovation and improve patient outcomes, today announced its debut investment in Bionic Power, a Canadian-based firm.
  • A developer of active lower body smart orthotic devices that enhance personal mobility, Bionic Power is raising Series A Round funding, with Hanger Ventures committing as the lead investor.
  • “We are thrilled to make our inaugural investment in Bionic Power,” shared James Campbell, Ph.D., Hanger Ventures President and Hanger, Inc. Chief Clinical Officer.
  • “When we learned about the creation of Hanger Ventures, we felt the opportunity was a great match for Bionic Power’s needs, and the subsequent discussions confirmed our initial impression,” shared Gualtiero Guadagni, Ph.D., Bionic Power Chief Executive Officer.

Blood Filtration Offers Hope in the Fight Against Pancreatic Cancer

Retrieved on: 
Thursday, July 18, 2024

In a groundbreaking advancement of a novel cancer treatment, researchers have successfully deployed Seraph® 100 blood filtration media to demonstrate removal of Circulating Tumor Cells (CTCs) from the blood of patients suffering from advanced pancreatic cancer.

Key Points: 
  • In a groundbreaking advancement of a novel cancer treatment, researchers have successfully deployed Seraph® 100 blood filtration media to demonstrate removal of Circulating Tumor Cells (CTCs) from the blood of patients suffering from advanced pancreatic cancer.
  • ONCObind™ uses the Seraph® 100 filtration media to filter circulating tumor cells from the blood.
  • "This device represents an opportunity to significantly improve the care for patients with pancreatic cancer and is potentially applicable to other forms of cancer."
  • In the study, blood samples of patients with pancreatic ductal adenocarcinoma (PDAC) underwent in vitro blood filtration using the Seraph® 100 media.

Surgical Robotics Simulation Market Analysis 2024: Benefits of Virtual Reality-Based Training for Surgical Skill Development Fuels Adoption - Global Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 18, 2024

The growth of the surgical robotics simulation market is driven by several factors, such as a reduction in medical errors, improved competence in high-risk procedures, and rising adoption of surgical robots, leading to increased demand for surgical robotics simulation products.

Key Points: 
  • The growth of the surgical robotics simulation market is driven by several factors, such as a reduction in medical errors, improved competence in high-risk procedures, and rising adoption of surgical robots, leading to increased demand for surgical robotics simulation products.
  • The surgical robotics simulation market is experiencing rapid growth, driven by the increasing adoption of robotic-assisted surgical procedures globally.
  • The hospitals segment is positioned to dominate the surgical robotics simulation market by end user, as hospitals use surgical robotics simulations to improve surgical outcomes and patient care.
  • The surgical robotics simulation market (by product type) was dominated by product segment, securing a share of 71.44% in 2023.

ICH and CDISC Collaborate to Support the Maintenance and Governance Process for ICH M11 Controlled Terminology

Retrieved on: 
Thursday, July 18, 2024

This protocol and electronic exchange format will facilitate the streamlining and exchange of protocol information and support future tool development.

Key Points: 
  • This protocol and electronic exchange format will facilitate the streamlining and exchange of protocol information and support future tool development.
  • ICH and CDISC (Clinical Data Interchange Standards Consortium) have signed a Memorandum of Understanding (MOU) collaborating to support the maintenance and governance of ICH M11 controlled terminology.
  • This collaboration focuses on the use of CDISC’s unified governance process and terminology services for the long-term support of ICH M11 controlled terminologies and focuses on the curation and maintenance of these controlled terminologies.
  • ICH and CDISC will support these goals and align activities to support the development, adoption, and implementation of these controlled terminologies.